dubermatinib

Dubermatinib is an orally available, potent, and selective small molecule inhibitor of the Axl receptor tyrosine kinase (also known as tyrosine-protein kinase receptor UFO), with additional inhibitory activity against aurora kinase B and Janus kinase 2. It is being developed primarily for the treatment of hematologic malignancies such as acute myeloid leukemia (AML) and chronic lymphocytic leukemia (CLL). Dubermatinib acts by blocking Axl signaling and Aurora B activation, leading to G2/M cell cycle arrest and promoting apoptosis in cancer cells. The drug has shown potential antineoplastic activity in preclinical models and is currently under investigation in phase I/II clinical trials for AML and CLL. It has also been studied preclinically for solid tumors including breast cancer, malignant melanoma, colorectal cancer, ovarian cancer, non-small-cell lung carcinoma, neuroblastoma, glioblastoma, head and neck cancer[2][3][5][7][8].

Other names

dubermatinibTP-0903TP0903TP 0903